Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...
Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...
Lilly's Ebglyss shown to be effective in former Dupixent users
Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...
Eli Lilly's Ebglyss Emerges as New Option for Patients Struggling with Dupixent Treatment
Ebglyss proves effective in relieving dermatitis symptoms, showing promise as a substitute for Dupixent in challenging cases ...
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to ...
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
Managed Healthcare Executive6d
Long-Term Dupixent Treatment Shows Promising Results for Severe Atopic Dermatitis
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Future Market Insights1h
Global Injection Pen Market Projected to Reach USD 85.8 Billion by 2033, Growing at a CAGR of 7.0%
The global injection pen market is poised for significant growth, with projections indicating a robust compound annual growth rate (CAGR) of 7.0% from 2022 to 2033. The market is expected to escalate ...
Sanofi announces presentation of Dupixent Phase 3 data in CSU
Data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent in biologic-naive patients with uncontrolled chronic ...
Pharmabiz2d
Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI
Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...
Eli Lilly gets nod to sell weight-loss drug in Hong Kong by year-end - report
Eli Lilly (NYSE:LLY) received approval from the Hong Kong government to launch its weight-loss drug—Mounjaro, with sales ...
Sanofi: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved ...